ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
2seventy bio Inc

2seventy bio Inc (TSVT)

2.59
0.20
(8.37%)
At close: 20 February 8:00AM
2.57
-0.02
( -0.77% )
After Hours: 8:03AM

Calls

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
2.500.000.000.000.000.000.00 %00-
5.000.000.000.000.000.000.00 %00-

Professional-Grade Tools, for Individual Investors.

Puts

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
2.500.000.000.000.000.000.00 %00-
5.000.000.000.000.000.000.00 %00-

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MNDRMobile health Network Solutions
US$ 0.4743
(44.03%)
2.32M
XOSXos Inc
US$ 4.24
(35.46%)
643.48k
RECTRectitude Holdings Ltd
US$ 4.40
(19.24%)
312
PWMPrestige Wealth Inc
US$ 0.69
(16.95%)
23.46k
NRDSNerdWallet Inc
US$ 16.1532
(15.46%)
50.19k
GRIGRI Bio Inc
US$ 0.42
(-22.85%)
60.63k
INSGInseego Corporation
US$ 9.84
(-16.68%)
3.95k
ZCARZoomcar Holdings Inc
US$ 0.6499
(-12.80%)
194.51k
INBSIntelligent Bio Solutions Inc
US$ 2.35
(-10.98%)
14.69k
BSLKBolt Projects Holdings Inc
US$ 0.628
(-8.05%)
98.14k
ADTXAditxt Inc
US$ 0.1203
(-6.60%)
6.83M
RGTIRigetti Computing Inc
US$ 10.9998
(-0.23%)
4.1M
BILIBilibili Inc
US$ 20.30
(-0.05%)
4.04M
SMCISuper Micro Computer Inc
US$ 59.30
(-1.60%)
2.35M
MNDRMobile health Network Solutions
US$ 0.489001
(48.50%)
2.34M

TSVT Discussion

View Posts
Monksdream Monksdream 6 months ago
TSVT under $5
👍️0
Monksdream Monksdream 10 months ago
TSVT under $5
👍️0
Invest-in-America Invest-in-America 11 months ago
TSVT: Big (Post-M) news for this Firm & partner Bristol Myers.

"Bristol Myers, 2seventy Bios Cancer Treatment Wins FDA Committee Approval
7:04 PM ET 3/15/24 | Dow Jones
By Ben Glickman Bristol Myers Squibb and 2seventy Bio's cancer treatment showed a favorable risk-benefit profile in certain populations, according to Food and Drug Administration committee. The Oncologic Drugs Advisory Committee voted 8-3 that Abecma, a gene therapy, had a favorable profile in the treatment of the blood cancer multiple myeloma, specifically in the triple-class exposed relapsed or refractory forms of the cancer, the companies said on Friday. Bristol Myers Squibb and 2seventy said the recommendation would be considered by the FDA in its review of their supplemental Biologics License Application. The FDA hasn't assigned a new target action date for reviewing that application, the companies said. Abecma was recently approved in Japan and Switzerland for patients with relapsed or refractory multiple myeloma who have received at least two prior therapies. Write to Ben Glickman at ben.glickman@wsj.com > Dow Jones Newswires March 15, 2024 19:04 ET (23:04 GMT)"
👍️0
Monksdream Monksdream 12 months ago
TSVT 10Q due March 5
👍️0
molee molee 1 year ago
$TSVT > A bit of "short covering" going on now ... How high ???
👍️0
Monksdream Monksdream 1 year ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👎️ 1
johnhancoque johnhancoque 1 year ago
2 seventy will be auctioned off in Bankruptcy court within a year. Cash on hand is 12 months or less.
👍️0
molee molee 1 year ago
C'mon man . What the heck . $2.00 now ? Really ?
👍️0

Your Recent History

Delayed Upgrade Clock